Use of human induced pluripotent stem cell–derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: a scientific statement from the American Heart …
It is now well recognized that many lifesaving oncology drugs may adversely affect the heart
and cardiovascular system, including causing irreversible cardiac injury that can result in …
and cardiovascular system, including causing irreversible cardiac injury that can result in …
Trastuzumab-induced cardiomyopathy
R Barish, E Gates, A Barac - Cardiology clinics, 2019 - cardiology.theclinics.com
In recent decades, cancer treatment has been revolutionized by molecular discoveries that
have provided new and more specific targets for therapy. 1 Human epidermal growth factor …
have provided new and more specific targets for therapy. 1 Human epidermal growth factor …
[HTML][HTML] Splice-junction-based mapping of alternative isoforms in the human proteome
The protein-level translational status and function of many alternative splicing events remain
poorly understood. We use an RNA sequencing (RNA-seq)-guided proteomics method to …
poorly understood. We use an RNA sequencing (RNA-seq)-guided proteomics method to …
Workshop report: FDA workshop on improving cardiotoxicity assessment with human-relevant platforms
Given that cardiovascular safety concerns remain the leading cause of drug attrition at the
preclinical drug development stage, the National Center for Toxicological Research of the …
preclinical drug development stage, the National Center for Toxicological Research of the …
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell
Abstract Treatment of cancer has evolved in the last decade with the introduction of new
therapies. Despite these successes, the lingering cardiotoxic side-effects from …
therapies. Despite these successes, the lingering cardiotoxic side-effects from …